Sign up to save your podcasts
Or
Share The Skinny on GLP-1s: Part 2
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Skinny on GLP-1s: Part 2
Welcome to Pharmacy Friends – we bring industry experts to
the same table to talk about what is happening in pharmacy today, what is coming, and most importantly, what it means to you.
A hot topic in the health care industry is GLP1s and chronic weight management. In this last segment of our two-part episode, our experts discuss Prime’s analysis of real-world integrated pharmacy and medical claims data.
Hosting today’s episode “The Skinny on GLP1s,” is Maryam
Tabatabai, vice president for clinical information. Joining her are two experts, David Lassen, a clinic pharmacist and Prime’s Chief Clinical Officer, who has strategic oversight of clinical services and support for customers. Pat Gleason, assistant vice president, leads Prime’s health outcomes team which performs deep dives into research data. These three experts discuss how their
data shows low adherence and increased costs in the first year and how they hope to see additional data to refine our guidance on GLP1s and chronic weight management approaches.
The Skinny on GLP-1s: Part 1
Real-world analysis of GLP-1a drugs for weight loss finds low adherence and increased cost in first year
All Pharmacy Friends episodes
https://www.primetherapeutics.com/
View all episodes
By Prime Therapeutics
5
1212 ratings
Welcome to Pharmacy Friends – we bring industry experts to
the same table to talk about what is happening in pharmacy today, what is coming, and most importantly, what it means to you.
A hot topic in the health care industry is GLP1s and chronic weight management. In this last segment of our two-part episode, our experts discuss Prime’s analysis of real-world integrated pharmacy and medical claims data.
Hosting today’s episode “The Skinny on GLP1s,” is Maryam
Tabatabai, vice president for clinical information. Joining her are two experts, David Lassen, a clinic pharmacist and Prime’s Chief Clinical Officer, who has strategic oversight of clinical services and support for customers. Pat Gleason, assistant vice president, leads Prime’s health outcomes team which performs deep dives into research data. These three experts discuss how their
data shows low adherence and increased costs in the first year and how they hope to see additional data to refine our guidance on GLP1s and chronic weight management approaches.
The Skinny on GLP-1s: Part 1
Real-world analysis of GLP-1a drugs for weight loss finds low adherence and increased cost in first year
All Pharmacy Friends episodes
https://www.primetherapeutics.com/